FDA Taking Nominations for List of Difficult-to-Compound Drugs

Drug Industry Daily
A A
The FDA established a public docket so companies can nominate drug products or categories for the agency’s Difficult to Compound List — which blocks pharmacies from compounding certain products unless they are listed as a manufacturer.

To View This Article:

Login

Subscribe To Drug Industry Daily